Orexin receptors exert a neuroprotective effect in Alzheimer's disease (AD) via heterodimerization with GPR103

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Davies, Julie ^a   Chen, Jing ^b,c   Pink, Ryan ^d   Carter, David ^d   Saunders, Nigel ^a   Sotiriadis, Georgios ^a   Bai, Bo ^c   Pan, Yanyou ^c   Howlett, David ^e   Payne, Annette ^a   Randeva, Harpal ^b,f   Karteris, Emmanouil ^a  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c JINING MEDICAL UNIVERSITY   (China)

^d OXFORD BROOKES UNIVERSITY   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OREXIN RECEPTOR; PEPTIDE FRAGMENT; QRFPR PROTEIN, HUMAN; RETINOIC ACID; TAU PROTEIN; ZINC SULFATE;

ADULT; ALZHEIMER DISEASE; CELL DIFFERENTIATION; CHEMISTRY; DIMERIZATION; DOWN REGULATION; DRUG EFFECT; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETICS; HEK293S CELL LINE; HIPPOCAMPUS; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADULT; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; CELL DIFFERENTIATION; CELL LINE, TUMOR; DIMERIZATION; DOWN-REGULATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEK293 CELLS; HIPPOCAMPUS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OREXIN RECEPTORS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, G-PROTEIN-COUPLED; TAU PROTEINS; TRETINOIN; ZINC SULFATE;

EID: 84938331166     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12584     Document Type: Article

References (44)

1. Thompson, M. D. et al. OX1 and OX2 orexin/hypocretin receptor pharmacogenetics. Front Neurosci 8, 1-12 (2014).
2. Xu, T. R. et al. Orexin receptors: multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cell Signal 25, 2413-2423 (2013).
3. Karteris, E. & Randeva, H. S. Orexin receptors and G-protein coupling: evidence for another "promiscuous" seven transmembrane domain receptor. J Pharmacol Sci. 93 126-128 (2003).
4. Kukkonen, J. P. & Leonard, C. S. Orexin/hypocretin receptor signalling cascades. Br J Pharmacol 171, 314-331 (2014).
5. Fronczek, R. et al. Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol Aging 33, 1642-1650 (2012).
6. Slats, D. et al. Association between hypocretin-1 and amyloid-? 42 cerebrospinal fluid levels in Alzheimer's disease and healthy controls. Curr Alzheimer Res 9, 1119-1125 (2012).
7. Deuschle, M. et al. Hypocretin in cerebrospinal fluid is positively correlated with Tau and pTau. Neurosci Lett 561, 41-45 (2014).
8. Jiang, Y. et al. Identification and characterization of a novel RF-Amide peptide ligand for orphan G-protein-coupled receptor SP9155. J Biol Chem 278, 27652-27657 (2003).
9. Ramanjaneya, M. et al. QRFP induces aldosterone production via PKC and T-type calcium channel-mediated pathways in human adrenocortical cells: evidence for a novel role of GPR103. Am J Physiol 305, 1049-1058 (2013).
10. Blennow, K., de Leon, M. J. & Zetterberg, H. Alzheimer's disease. Lancet 368, 387-403 (2006).
11. Harper, D. G. et al. Differential circadian rhythm disturbances in men with Alzheimer disease and frontotemporal degeneration. Arch Gen Psychiatry 58, 353-360 (2001).
12. Akbari, E., Motamedi, F., Naghdi, N. & Noorbakhshnia, M. The effect of antagonization of orexin 1 receptors in CA1 and dentate gyrus regions on memory processing in passive avoidance task. Behav Brain Res 187, 172-177 (2008).
13. Akbari, E., Naghdi, N. & Motamedi, F. Functional inactivation of orexin 1 receptors in CA1 region impairs acquisition, consolidation and retrieval in Morris water maze task. Behav Brain Res 173, 47-52 (2006).
14. Davies, J., Zachariades, E., Rogers-Broadway, K. R. & Karteris, E. Elucidating the role of DEPTOR in Alzheimer's disease. Int J Mol Med 34, 1195-200 (2014).
15. Deshpande, A., Win, K. M. & Busciglio, J. Tau isoform expression and regulation in human cortical neurons. FASEB J 22, 2357-67 (2008).
16. Benilova, I. Karran, E. & De Strooper, B. The toxic A oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 15, 349-357 (2012).
17. Carlson, G. A. A welcoming environment for amyloid plaques. Nat Neurosci 6, 328-330 (2003).
18. Karmarkar, S. W. Bottum, K. M., Krager, S. L. & Tischkau, S. A. ERK/MAPK is essential for endogenous neuroprotection in SCN2.2 cells. PLoS One 6, e23493 (2011).
19. Maher, P. et al. ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum Mol Genet 20, 261-270 (2011).
20. Sokoowska, P. et al. Orexins protect neuronal cell cultures against hypoxic stress: an involvement of akt signalling. J Mol Neurosci 52, 48-55 (2014).
21. Crampton, S. J. & O'Keeffe, G. W. NF-kappaB: emerging roles in hippocampal development and function. Int J Biochem Cell Biol 52, 48-55 (2014).
22. Bai, B., Cai, X., Jiang, Y., Karteris, E. & Chen, J. Heterodimerization of apelin receptor and neurotensin receptor 1 induces phosphorylation of ERK(1/2) and cell proliferation via G? q-mediated mechanism. J Cell Mol Med 18, 2071-2081 (2014).
23. Zhang, Q. et al. Involvement of ERK1/2 pathway in neuroprotective effects of pyrroloquinoline quinine against rotenone-induced SH-SY5Y cell injury. Neuroscience 270, 183-191 (2014).
24. Mparmpakas, D., Zachariades, E., Goumenou, A., Gidron, Y. & Karteris, E. Placental DEPTOR as a stress sensor during pregnancy. Clin Sci (Lond) 122, 349-359 (2012).
25. Lohse, M. J., Nuber, S. & Hoffmann, C. Fluorescence/bioluminescence resonance energy transfer techniques to study G-proteincoupled receptor activation and signaling. Pharmacol Rev 64, 299-336 (2012).
26. Shan, X. & Lin, C. L. Quantification of oxidized RNAs in Alzheimer's disease. Neurobiol Aging 27, 657-662 (2006).
27. Liu, J. et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-Alpha-lipoic acid. PNAS 99, 2356-2361 (2002)
28. Marchal, J. et al. Calorie restriction and resveratrol supplementation prevent age-related DNA and RNA oxidative damage in a non-human primate. Exp Gerontol 48, 992-1000 (2013).
29. Porkka-Heiskanen, T., Alanko, L., Kalinchuk, A., Heiskanen, S. & Stenberg, D. The effect of age on prepro-orexin gene expression and contents of orexin A and B in the rat brain. Neurobiol Aging 25, 231-238 (2004).
30. Terao, A., Apte-Deshpande, A., Morairty, S., Freund, Y. R. & Kilduff, T. S. Age-related decline in hypocretin (orexin) receptor 2 messenger RNA levels in the mouse brain. Neurosci Lett 332, 190-194 (2002).
31. Kang, J. E. et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle". Science 326, 1005-1007 (2009).
32. Song, M., Xiong, J. X., Wang, Y. Y., Tang, J., Zhang, B. & Bai, Y. VIP enhances phagocytosis of fibrillar beta-Amyloid by microglia and attenuates amyloid deposition in the brain of APP/PS1 mice. PloS One 7, e29790 (2012).
33. Hama, E. & Saido, T. C. Etiology of sporadic Alzheimer's disease: somatostatin, neprilysin, and amyloid beta peptide. Med Hypotheses 65, 498-500 (2005).
34. Lee, S. T. et al. Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-beta burden in Alzheimer's disease models. J Neurochem 120, 115-124 (2012).
35. Li, X., Alafuzoff, I., Soininen, H., Winblad, B. & Pei, J. J. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J 272, 4211-4220 (2005).
36. Pedersen, W. A. et al. Corticotropin-releasing hormone protects neurons against insults relevant to the pathogenesis of Alzheimer's disease. Neurobiol Disease 8, 492-503 (2001).
37. Sagare, A. P. et al. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun 4, 2932 (2013).
38. Karteris, E. et al. Food deprivation differentially modulates orexin receptor expression and signaling in rat hypothalamus and adrenal cortex. Am J Physiol Endocrinol Metab 288, 1089-100 (2005).
39. Ukena, K., Osugi, T., Leprince, J., Vaudry, H. & Tsutsui, K. Molecular evolution of GPCRs: 26Rfa/GPR103. J Mol Endocrinol 52, 119-131 (2014).
40. Latek, D., Modzelewska, A., Trzaskowski, B., Palczewski, K. & Filipek, S. G protein-coupled receptors-recent advances. Acta Biochim Pol 59, 515-529 (2012).
41. Naumenko, V. S., Popova, N. K., Lacivita, E., Leopoldo, M. & Ponimaskin, E. G. Interplay between serotonin 5-HT1A and 5-HT7 receptors in depressive disorders. CNS Neurosci Ther 20, 582-590 (2014).
42. AbdAlla, S. et al. Dominant negative AT2 receptor oligomers induce G-protein arrest and symptoms of neurodegeneration. J Biol Chem 284, 6566-74 (2009).
43. Jäntti, M. H., Mandrika, I. & Kukkonen, J. P. Human orexin/hypocretin receptors form constitutive homo-And heteromeric complexes with each other and with human CB1 cannabinoid receptors. Biochem Biophys Res Commun 445, 486-490 (2014).
44. Bruzzone, F. et al. Distribution of 26RFa binding sites and GPR103 mRNA in the central nervous system of the rat. J Comp Neurol 503, 573-591 (2007).